QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) An erratum has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chaipatikul, V. Articles by Law, P.-Y. Search for Related Content PubMed PubMed Citation Articles by Chaipatikul, V. Articles by Law, P.-Y.

Rescuing the Traffic-Deficient Mutants of Rat µ-Opioid Receptors with Hydrophobic Ligands

Department of Pharmacology, Medical School, University of Minnesota, Minneapolis, Minnesota

Deletion of a sequence near the fifth transmembrane domain (²⁵⁸RLSKV²⁶², i3-1 mutant) and a motif residing at the proximal carboxyl tail (³⁴⁴KFCTR³⁴⁸, C-2 mutant) resulted in µ-opioid receptor mutants that were poorly expressed on the surface of transfected human embryonic kidney 293 cells. Treatment with the opioid antagonist naloxone, the agonist etorphine, and other hydrophobic ligands enhanced cell surface expression of i3-1 and C-2 mutants. The observed enhancement was time- and concentration-dependent, required the ligands to be membrane permeable, and was not the result of the reversal of the constitutive activities of the mutant receptors. The binding of the ligands resulted in the trafficking of the mutant receptors retained in the endoplasmic reticulum to the cell surface. The cell surface-expressed mutant C-2, but not i3-1, fully retained ability to mediate inhibition of adenylyl cyclase activity. Furthermore, the Golgi-disturbing agents brefeldin A and monensin completely blocked naloxone-enhanced expression of i3-1 and C-2 mutants. Results of these studies suggest that intracellular interactions of agonist and antagonist with mutant receptors can serve as chaperones in the trafficking of the mutants to the cell surface.

Received January 3, 2003; accepted March 31, 2003.

Address correspondence to: Ping-Yee Law, Department of Pharmacology, Medical School, University of Minnesota, 6-120 Jackson Hall, 321 Church Street S.E., Minneapolis, MN 55455. E-mail: lawxx001{at}umn.edu

This article has been cited by other articles:

				X. Ge, H. H. Loh, and P.-Y. Law {micro}-Opioid Receptor Cell Surface Expression Is Regulated by Its Direct Interaction with Ribophorin I Mol. Pharmacol., June 1, 2009; 75(6): 1307 - 1316. [Abstract] [Full Text] [PDF]

				K. M. Wannemacher, P. N. Yadav, and R. D. Howells A Select Set of Opioid Ligands Induce Up-Regulation by Promoting the Maturation and Stability of the Rat {kappa}-Opioid Receptor in Human Embryonic Kidney 293 Cells J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 614 - 625. [Abstract] [Full Text] [PDF]

				P. M. Conn, A. Ulloa-Aguirre, J. Ito, and J. A. Janovick G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo Pharmacol. Rev., September 1, 2007; 59(3): 225 - 250. [Abstract] [Full Text] [PDF]

				T. T. Leskela, P. M. H. Markkanen, E. M. Pietila, J. T. Tuusa, and U. E. Petaja-Repo Opioid Receptor Pharmacological Chaperones Act by Binding and Stabilizing Newly Synthesized Receptors in the Endoplasmic Reticulum J. Biol. Chem., August 10, 2007; 282(32): 23171 - 23183. [Abstract] [Full Text] [PDF]

				Y. Chen, C. Chen, Y. Wang, and L.-Y. Liu-Chen Ligands Regulate Cell Surface Level of the Human {kappa} Opioid Receptor by Activation-Induced Down-Regulation and Pharmacological Chaperone-Mediated Enhancement: Differential Effects of Nonpeptide and Peptide Agonists J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 765 - 775. [Abstract] [Full Text] [PDF]

				K. N. Browning, Z. Zheng, T. W. Gettys, and R. A. Travagli Vagal afferent control of opioidergic effects in rat brainstem circuits J. Physiol., September 15, 2006; 575(3): 761 - 776. [Abstract] [Full Text] [PDF]

				S. R. Hawtin Pharmacological Chaperone Activity of SR49059 to Functionally Recover Misfolded Mutations of the Vasopressin V1a Receptor J. Biol. Chem., May 26, 2006; 281(21): 14604 - 14614. [Abstract] [Full Text] [PDF]

				J.-P. Fortin, E. K. Dziadulewicz, L. Gera, and F. Marceau A Nonpeptide Antagonist Reveals a Highly Glycosylated State of the Rabbit Kinin B1 Receptor Mol. Pharmacol., April 1, 2006; 69(4): 1146 - 1157. [Abstract] [Full Text] [PDF]

				J. Robert, C. Auzan, M. A. Ventura, and E. Clauser Mechanisms of Cell-surface Rerouting of an Endoplasmic Reticulum-retained Mutant of the Vasopressin V1b/V3 Receptor by a Pharmacological Chaperone J. Biol. Chem., December 23, 2005; 280(51): 42198 - 42206. [Abstract] [Full Text] [PDF]

				S. Roy, J. Wang, R. Charboneau, H. H. Loh, and R. A. Barke Morphine Induces CD4+ T Cell IL-4 Expression through an Adenylyl Cyclase Mechanism Independent of the Protein Kinase A Pathway J. Immunol., November 15, 2005; 175(10): 6361 - 6367. [Abstract] [Full Text] [PDF]

				P.-Y. Law, L. J. Erickson-Herbrandson, Q. Q. Zha, J. Solberg, J. Chu, A. Sarre, and H. H. Loh Heterodimerization of {micro}- and {delta}-Opioid Receptors Occurs at the Cell Surface Only and Requires Receptor-G Protein Interactions J. Biol. Chem., March 25, 2005; 280(12): 11152 - 11164. [Abstract] [Full Text] [PDF]

				K. N. Browning, A. E. Kalyuzhny, and R. A. Travagli {micro}-Opioid Receptor Trafficking on Inhibitory Synapses in the Rat Brainstem J. Neurosci., August 18, 2004; 24(33): 7344 - 7352. [Abstract] [Full Text] [PDF]